Compare HSY & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSY | TAK |
|---|---|---|
| Founded | 1894 | 1781 |
| Country | United States | Japan |
| Employees | 17550 | 47455 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.9B | 56.5B |
| IPO Year | 2004 | N/A |
| Metric | HSY | TAK |
|---|---|---|
| Price | $209.57 | $17.83 |
| Analyst Decision | Hold | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $215.07 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 2.76% | ★ 2.91% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $8,149,719,000.00 | N/A |
| Revenue This Year | $5.73 | $0.04 |
| Revenue Next Year | $2.35 | $0.92 |
| P/E Ratio | $329.76 | ★ $41.25 |
| Revenue Growth | ★ 2.05 | N/A |
| 52 Week Low | $150.04 | $12.99 |
| 52 Week High | $239.48 | $18.82 |
| Indicator | HSY | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 47.23 |
| Support Level | $176.95 | $17.51 |
| Resistance Level | $237.17 | $18.82 |
| Average True Range (ATR) | 4.81 | 0.26 |
| MACD | -2.86 | -0.08 |
| Stochastic Oscillator | 2.13 | 31.77 |
Hershey is a leading US confectionery manufacturer (around a $54 billion market, according to Euromonitor), controlling around 36% of the domestic chocolate aisle. Beyond its namesake label, the firm's portfolio has expanded over the last 85 years and now comprises 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the US, including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confectionery business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its portfolio, as well as Pirate Brands and Dot's Pretzels over the past few years.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.